์ฝ˜ํ…์ธ ๋กœ ๊ฑด๋„ˆ๋›ฐ๊ธฐ
Merck
๋ชจ๋“  ์‚ฌ์ง„(1)

์ฃผ์š” ๋ฌธ์„œ

286818

Sigma-Aldrich

Neostigmine methyl sulfate

98%

๋™์˜์–ด(๋“ค):

3-(N,N-Dimethylcarbamoyloxy)-N,N,N,-trimethylanilinium methyl sulfate

๋กœ๊ทธ์ธ์กฐ์ง ๋ฐ ๊ณ„์•ฝ ๊ฐ€๊ฒฉ ๋ณด๊ธฐ


About This Item

์‹คํ—˜์‹(Hill ํ‘œ๊ธฐ๋ฒ•):
C13H22N2O6S
CAS Number:
Molecular Weight:
334.39
EC Number:
MDL number:
UNSPSC ์ฝ”๋“œ:
12352103

๋ถ„์„

98%

SMILES string

COS([O-])(=O)=O.CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C

InChI

1S/C12H19N2O2.CH4O4S/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5;1-5-6(2,3)4/h6-9H,1-5H3;1H3,(H,2,3,4)/q+1;/p-1

InChI key

OSZNNLWOYWAHSS-UHFFFAOYSA-M

์œ ์‚ฌํ•œ ์ œํ’ˆ์„ ์ฐพ์œผ์‹ญ๋‹ˆ๊นŒ? ๋ฐฉ๋ฌธ ์ œํ’ˆ ๋น„๊ต ์•ˆ๋‚ด

์ƒํ™”ํ•™์ /์ƒ๋ฆฌํ•™์  ์ž‘์šฉ

Reversible inhibitor of acetylcholinesterase that is similar to eserine, but does not cross the blood-brain barrier.
Reversible inhibitor of acetylcholinesterase; does not cross the blood-brain barrier.

ํ”ฝํ† ๊ทธ๋žจ

Skull and crossbonesHealth hazard

์‹ ํ˜ธ์–ด

Danger

์œ ํ•ด ๋ฐ ์œ„ํ—˜ ์„ฑ๋ช…์„œ

์˜ˆ๋ฐฉ์กฐ์น˜ ์„ฑ๋ช…์„œ

Hazard Classifications

Acute Tox. 2 Oral - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - STOT SE 3

ํ‘œ์  ๊ธฐ๊ด€

Respiratory system

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flash Point (ยฐF)

Not applicable

Flash Point (ยฐC)

Not applicable

๊ฐœ์ธ ๋ณดํ˜ธ ์žฅ๋น„

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges


๊ฐ€์žฅ ์ตœ์‹  ๋ฒ„์ „ ์ค‘ ํ•˜๋‚˜๋ฅผ ์„ ํƒํ•˜์„ธ์š”:

์‹œํ—˜ ์„ฑ์ ์„œ(COA)

Lot/Batch Number

์ ํ•ฉํ•œ ๋ฒ„์ „์„ ์ฐพ์„ ์ˆ˜ ์—†์œผ์‹ ๊ฐ€์š”?

ํŠน์ • ๋ฒ„์ „์ด ํ•„์š”ํ•œ ๊ฒฝ์šฐ ๋กœํŠธ ๋ฒˆํ˜ธ๋‚˜ ๋ฐฐ์น˜ ๋ฒˆํ˜ธ๋กœ ํŠน์ • ์ธ์ฆ์„œ๋ฅผ ์ฐพ์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

์ด ์ œํ’ˆ์„ ์ด๋ฏธ ๊ฐ€์ง€๊ณ  ๊ณ„์‹ญ๋‹ˆ๊นŒ?

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ์—์„œ ์ตœ๊ทผ์— ๊ตฌ๋งคํ•œ ์ œํ’ˆ์— ๋Œ€ํ•œ ๋ฌธ์„œ๋ฅผ ์ฐพ์•„๋ณด์„ธ์š”.

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ ๋ฐฉ๋ฌธ

Michael Benatar et al.
The Cochrane database of systematic reviews, 12, CD005081-CD005081 (2012-12-14)
Approximately 50% of people with myasthenia gravis present with purely ocular symptoms, so called ocular myasthenia. Of these between 50% to 60% develop generalized disease, most within two years. Their management is controversial. This is an update of a review
A reply.
G Geldner et al.
Anaesthesia, 68(3), 307-308 (2013-02-07)
Tetsufumi Sato et al.
Masui. The Japanese journal of anesthesiology, 62(1), 19-26 (2013-02-26)
Anticholinesterase, such as neostigmine, was used to be a standard drug at the end of surgery for reversal of nondepolarizing neuromuscular block. Neostigmine decreases the metabolism of acetylcholine (ACh) at the neuromuscular junction and allows its concentration to increase and
Jakub Fichna et al.
Pharmacological reports : PR, 64(5), 1146-1154 (2012-12-15)
Animal models of visceral pain have gained much attention as an important tool to elucidate the possible mechanisms underlying functional gastrointestinal (GI) disorders. Here we report the development of a new, minimally invasive behavioral model of abdominal pain induced by
Oyun Khookhor et al.
Neuro endocrinology letters, 34(1), 58-61 (2013-03-26)
We previously demonstrated that the direct microinjection of cholinesterase inhibitor (neostigmine) into the hippocampus in rats activated the hypothalamo-pituitary -adrenal axis and increased the level of norepinephrine in the plasma. In the current study we tried to measure the effects

์ž์‚ฌ์˜ ๊ณผํ•™์žํŒ€์€ ์ƒ๋ช… ๊ณผํ•™, ์žฌ๋ฃŒ ๊ณผํ•™, ํ™”ํ•™ ํ•ฉ์„ฑ, ํฌ๋กœ๋งˆํ† ๊ทธ๋ž˜ํ”ผ, ๋ถ„์„ ๋ฐ ๊ธฐํƒ€ ๋งŽ์€ ์˜์—ญ์„ ํฌํ•จํ•œ ๋ชจ๋“  ๊ณผํ•™ ๋ถ„์•ผ์— ๊ฒฝํ—˜์ด ์žˆ์Šต๋‹ˆ๋‹ค..

๊ณ ๊ฐ์ง€์›ํŒ€์œผ๋กœ ์—ฐ๋ฝ๋ฐ”๋ž๋‹ˆ๋‹ค.